Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NHjhcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrMTWM2OD1yLk[xNlM4KM7:TR?= NUfCUJNbW0GQR1XS
H4 NGjlTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwNk[yPEDPxE1? M4DG[XNCVkeHUh?=
PA-1 M2nFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fNTGlEPTB;MD64O|A6PiEQvF2= M1PSZ3NCVkeHUh?=
NKM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDnTWM2OD1zLkC0PVMyKM7:TR?= MXHTRW5ITVJ?
NEC8 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXETWM2OD1zLkKxOVczKM7:TR?= NIfufItUSU6JRWK=
EoL-1-cell Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHuOGJKSzVyPUGuNlY4ODFizszN MkPjV2FPT0WU
K5 M2DYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwNEKwO|Ih|ryP MYjTRW5ITVJ?
QIMR-WIL M3PIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwNkC4OVQh|ryP MkP1V2FPT0WU
MOLT-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHS[mJHUUN3ME2xMlc5PjB2IN88US=> NEjPdIxUSU6JRWK=
CHP-212 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofqTWM2OD1zLkixN|Y6KM7:TR?= Ml7MV2FPT0WU
CTB-1 M2HlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTKTWM2OD1{LkCyNlQ3KM7:TR?= NX2zSJU2W0GQR1XS
MOLT-4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSxTWM2OD1{LkOyPFU{KM7:TR?= MXzTRW5ITVJ?
A101D NI\He3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwM{WwNUDPxE1? MnnmV2FPT0WU
DOHH-2 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\CeIpKSzVyPUKuOFIzPzlizszN NF\zbFdUSU6JRWK=
ES4 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TsWmlEPTB;Mj60N|E2PSEQvF2= NIm1SldUSU6JRWK=
SW780 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWwTWM2OD1{LkWwPFg{KM7:TR?= MWPTRW5ITVJ?
VA-ES-BJ NXjhOGtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJwNUSxNUDPxE1? M2G1PHNCVkeHUh?=
RPMI-8866 M{n3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLUTWM2OD1{LkW2NlE1KM7:TR?= MWTTRW5ITVJ?
ML-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr5TlY4UUN3ME2yMlU3PTd4IN88US=> MV3TRW5ITVJ?
MSTO-211H MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TCWWlEPTB;Mj61O|Q2OSEQvF2= NUDM[m96W0GQR1XS
JVM-3 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwNUmzNlQh|ryP Ml3BV2FPT0WU
A3-KAW NYHTboM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G0NmlEPTB;Mj62NVgyQCEQvF2= MoX4V2FPT0WU
DK-MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PQVWlEPTB;Mj62NlQ4OSEQvF2= MmXNV2FPT0WU
LNCaP-Clone-FGC MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\YZmlEPTB;Mj62OFMyQCEQvF2= NHz6OnJUSU6JRWK=
HT-144 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjBcoJyUUN3ME2yMlY1PTd5IN88US=> M1vvcnNCVkeHUh?=
NB69 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzLeGFKSzVyPUKuOlU{OzRizszN NUD0XpFQW0GQR1XS
A172 M4nTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwNke1PFgh|ryP NGXzUXVUSU6JRWK=
RS4-11 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQWYlKSzVyPUKuO|I1ODdizszN M{XyTHNCVkeHUh?=
DU-4475 NYTL[3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwN{m1NFIh|ryP NF3leIZUSU6JRWK=
SJSA-1 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m5UWlEPTB;Mj64NlU2PiEQvF2= NV3o[XRiW0GQR1XS
BV-173 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nxdGlEPTB;Mj64OFQ{QSEQvF2= NYD2PWozW0GQR1XS
U-2-OS NVXITVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCzTWM2OD1{LkmxNFch|ryP NH7VdlZUSU6JRWK=
CHP-134 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rC[mlEPTB;Mj65N|g5OiEQvF2= MWrTRW5ITVJ?
D-502MG M{\VZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;aeHVKSzVyPUKuPVcyPTRizszN NWLodmU2W0GQR1XS
KS-1 M2fPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNwMEG2NlMh|ryP NWnSNZp4W0GQR1XS
A204 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwMEW1PFgh|ryP M3LSOXNCVkeHUh?=
KGN NFzndHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm3R2dzUUN3ME2zMlA5PDl4IN88US=> Mlz1V2FPT0WU
NCI-H292 NUToVZRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7lbGx3UUN3ME2zMlEzODJ6IN88US=> NVexOnFtW0GQR1XS
CAKI-1 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHIc2RSUUN3ME2zMlEzPjl2IN88US=> MUjTRW5ITVJ?
C2BBe1 NF3qXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[zOVJKSzVyPUOuNVcxOjZizszN MkLyV2FPT0WU
NB10 NWLkXFVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XCVWlEPTB;Mz6yNFk3PiEQvF2= MnHjV2FPT0WU
MHH-NB-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvacFBKSzVyPUOuNlY5OjdizszN MoPpV2FPT0WU
NCI-SNU-1 NHzZeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXjPGNKSzVyPUOuNlc5PDNizszN M3;ne3NCVkeHUh?=
HCT-116 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfleXV7UUN3ME2zMlMxOzN3IN88US=> NYPkPJdyW0GQR1XS
G-401 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwM{[zNlIh|ryP MnPlV2FPT0WU
MN-60 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HncGlEPTB;Mz60OFA6OiEQvF2= NYr4d4VEW0GQR1XS
SW982 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3G[VRsUUN3ME2zMlUxQDR6IN88US=> Mn;jV2FPT0WU
RKO NV[yWJdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwNUO5N|Yh|ryP M2jsUHNCVkeHUh?=
D-283MED Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nzfmlEPTB;Mz61O|k5PiEQvF2= M2P2W3NCVkeHUh?=
LB996-RCC NGXsOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[5cmI5UUN3ME2zMlYzPTV6IN88US=> MnjDV2FPT0WU
A549 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHYZm5zUUN3ME2zMlY{PTV{IN88US=> M2\lPHNCVkeHUh?=
LB2241-RCC MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwNkW3NFgh|ryP NIqwbmpUSU6JRWK=
SK-HEP-1 NYDmU3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHvd4NKSzVyPUOuO|QzQTdizszN NGfuTpdUSU6JRWK=
G-402 NUK2TY1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHqSmJKSzVyPUOuPFA5OzJizszN MXXTRW5ITVJ?
GOTO M3;RNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETIbGlKSzVyPUOuPFQ{OzNizszN NUTlZVN4W0GQR1XS
LOXIMVI NHXJcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNwOEW2O|Uh|ryP M13yfHNCVkeHUh?=
NH-12 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwMEG5OVkh|ryP NIj6dGxUSU6JRWK=
CTV-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\MUnlKSzVyPUSuNFc6PzNizszN Mkm0V2FPT0WU
CP50-MEL-B NGC5clRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwMkSzPVIh|ryP MlS2V2FPT0WU
RH-18 NIfhdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfZZllKSzVyPUSuNlc4ODZizszN NVnKPW86W0GQR1XS
NB17 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnWTWM2OD12LkOxO|Y5KM7:TR?= MXHTRW5ITVJ?
A375 NH3LfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwM{O1NlQh|ryP MmfkV2FPT0WU
IST-MES1 NFLXUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInIdVdKSzVyPUSuOFE1OTFizszN NHvpV25USU6JRWK=
MZ2-MEL NHvPN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vQWGlEPTB;ND61NFE2PSEQvF2= NWXOVXQ6W0GQR1XS
CAL-54 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTFfYtKSzVyPUSuOVMxOTlizszN NYLZSGlZW0GQR1XS
NCI-H28 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRwNkK3NVch|ryP M173eHNCVkeHUh?=
D-247MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXXRXdKSzVyPUSuO|UxPzJizszN NW\YZ5lUW0GQR1XS
NCI-H460 NHz1T2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlThTWM2OD12LkmxNVI4KM7:TR?= MX;TRW5ITVJ?
MCF7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVwNESyOFQh|ryP MVLTRW5ITVJ?
697 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fnSmlEPTB;NT60OFU2KM7:TR?= NVvUVHAzW0GQR1XS
ONS-76 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwNUewNFkh|ryP MljhV2FPT0WU
C32 NVm3NFljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzYTINRUUN3ME21MlYxODJ7IN88US=> NIryOmxUSU6JRWK=
OS-RC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPFTWM2OD13LkezPFg4KM7:TR?= MXPTRW5ITVJ?
MEL-HO MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVwOEW2Olch|ryP NFSwVFVUSU6JRWK=
LoVo NWThT3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jHNmlEPTB;Nj6wNVYzPCEQvF2= MX\TRW5ITVJ?
AGS M33Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvRRmdKSzVyPU[uNVQ5OjhizszN MVTTRW5ITVJ?
GI-ME-N NF;qVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnYNXJKSzVyPU[uNlI1OjFizszN M3j6[HNCVkeHUh?=
H-EMC-SS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TEZmlEPTB;Nj6zPFYh|ryP M1v4b3NCVkeHUh?=
RVH-421 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnXSGloUUN3ME22MlQzPDJ6IN88US=> NF2wNFdUSU6JRWK=
SW954 NGXHdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\XcpJKSzVyPU[uOVU2PzJizszN Ml7mV2FPT0WU
NB5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTZwNU[xPFMh|ryP MUPTRW5ITVJ?
NCI-H2122 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrITWM2OD14LkW4O|k{KM7:TR?= Mk\4V2FPT0WU
AM-38 M3:x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXXWopKSzVyPU[uO|U3OzlizszN NUjKZWViW0GQR1XS
KNS-81-FD M4W3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnuVVFKSzVyPU[uO|Y1QTRizszN NWm4eY9vW0GQR1XS
LS-513 NVzOUGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7NTWM2OD14Lke5NFI3KM7:TR?= NFuwdldUSU6JRWK=
A427 M4XHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrJbJBFUUN3ME22Mlg4QDJ7IN88US=> MXTTRW5ITVJ?
WM-115 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HObWlEPTB;Nj65N|I{KM7:TR?= NXfSTm5lW0GQR1XS
COLO-829 NEfRRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDPTWM2OD15LkK0NVg5KM7:TR?= NIfIZ5BUSU6JRWK=
NCI-H1650 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLadmJoUUN3ME23MlM6OjJ6IN88US=> MnPrV2FPT0WU
NCI-H358 NFG4e|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwNES4O|kh|ryP MoPSV2FPT0WU
HT-1080 NHHsUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdwNEiyOVQh|ryP NHjrVI5USU6JRWK=
HCC2218 NVrmOnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfhU5NKSzVyPUeuOlI6PyEQvF2= MnjZV2FPT0WU
NCI-H661 M1q4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;pb2lEPTB;Nz64O|A3QSEQvF2= MVvTRW5ITVJ?
KM-H2 M3;wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nG[WlEPTB;Nz64PFY6PCEQvF2= NH32fYdUSU6JRWK=
RPMI-2650 M2TzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELsbVRKSzVyPUeuPVQ1OTRizszN MkLhV2FPT0WU
NCI-H226 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPINFdbUUN3ME24MlIyOTJ{IN88US=> NUft[YlKW0GQR1XS
MKN45 NVK3bIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRThwMk[2NFIh|ryP MmjSV2FPT0WU
D-392MG NEf5NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLjTWM2OD16LkWyO|IzKM7:TR?= MoXVV2FPT0WU
RCC10RGB NGrEPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRThwOE[2PVUh|ryP MkLYV2FPT0WU
CAL-51 NYfkUoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXSbZRKSzVyPUmuNVAzPTFizszN NFvJdXBUSU6JRWK=
COLO-678 M2XDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jqb2lEPTB;OT6zNlgyOSEQvF2= NVWxR|B1W0GQR1XS
SK-MEL-24 M1nUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;KT2lEPTB;OT61OVg2PiEQvF2= NYrsNmQ1W0GQR1XS
SK-MEL-30 NEjKN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTlwOUS0O|Yh|ryP NGracoFUSU6JRWK=
MMAC-SF MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XPZ2lEPTB;MUCuN|k3OSEQvF2= M2TKfXNCVkeHUh?=
NTERA-S-cl-D1 M{fiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61dGFzUUN3ME2xNE43PTB6IN88US=> MYPTRW5ITVJ?
NB12 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;vR21KSzVyPUGxMlUxOyEQvF2= MmX3V2FPT0WU
UACC-257 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFzLki2PVUh|ryP M17h[HNCVkeHUh?=
LAN-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTHTWM2OD1zMT65PVI5KM7:TR?= M33tO3NCVkeHUh?=
SW1573 M17HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDOTWM2OD1zMj6zNFg3KM7:TR?= M4\6W3NCVkeHUh?=
NMC-G1 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnQWY1iUUN3ME2xNk41OTd3IN88US=> MVPTRW5ITVJ?
SHP-77 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2niW2lEPTB;MUKuOVU4PCEQvF2= MoPPV2FPT0WU
IGROV-1 MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDZW3NKSzVyPUGyMlY2PzNizszN MYfTRW5ITVJ?
22RV1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF{LkiwOVkh|ryP MU\TRW5ITVJ?
SK-MEL-3 M1vKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK0O|NCUUN3ME2xN{4{QTd|IN88US=> MUHTRW5ITVJ?
NCI-H1563 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF60TlNKSzVyPUGzMlQzODJizszN MmC2V2FPT0WU
IGR-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe0Zpd6UUN3ME2xOE4xOzR5IN88US=> M4fZW3NCVkeHUh?=
EW-3 NVzjZo9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWyTWM2OD1zND6xOlM6KM7:TR?= M3S4SXNCVkeHUh?=
JEG-3 M3XsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF2LkS5OVMh|ryP MUXTRW5ITVJ?
ES3 NUnL[GxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF2Lk[1OlIh|ryP NXv2dlI3W0GQR1XS
MDA-MB-175-VII Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF2LkexNVEh|ryP NUXIbowxW0GQR1XS
P30-OHK MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPsTWM2OD1zNT6wOFk3KM7:TR?= NW\pZYN3W0GQR1XS
GP5d MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3LkG0OlYh|ryP NVfN[ZBwW0GQR1XS
HMV-II NV32Sm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjMR3NKSzVyPUG1MlM{OzNizszN NFe5d5BUSU6JRWK=
COLO-679 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Hk[WlEPTB;MUWuOVAyKM7:TR?= NYHH[I8yW0GQR1XS
JAR M{jZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfLNmJKSzVyPUG1MlczODVizszN NFzNcVdUSU6JRWK=
NCI-H1666 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJ[2lEPTB;MUWuPVM6QSEQvF2= Mnv1V2FPT0WU
SW48 NUTtOpZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLDTWM2OD1zNT65OVE3KM7:TR?= MUDTRW5ITVJ?
NCI-H720 M2naOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLkTWM2OD1zNT65PVg6KM7:TR?= M{jiWHNCVkeHUh?=
HT-1197 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1zNj6wN|UzKM7:TR?= MVzTRW5ITVJ?
HL-60 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF4LkCzPFQh|ryP NHj4NnpUSU6JRWK=
BEN M2TiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF4LkW2N|gh|ryP MmDTV2FPT0WU
HAL-01 NH\2NldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjtTWM2OD1zNj64PVA6KM7:TR?= MWjTRW5ITVJ?
SW900 NIfv[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7hSnBOUUN3ME2xOk46OTN{IN88US=> M{HpN3NCVkeHUh?=
SBC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW5TWM2OD1zNz61OFI6KM7:TR?= NFPONIlUSU6JRWK=
SH-4 NUPBNYplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF5LkW4OFEh|ryP NWLySlJIW0GQR1XS
UACC-62 M2D5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF5Lke2N|ch|ryP MnroV2FPT0WU
BHT-101 NETYSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkftTWM2OD1zOT64O|A2KM7:TR?= M2XhOHNCVkeHUh?=
DB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJzLkW2OFkh|ryP NFTabFBUSU6JRWK=
SK-MEL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nwfWlEPTB;MkGuOVg4OiEQvF2= MYjTRW5ITVJ?
NCI-H747 NXLBeVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJ{LkezO|kh|ryP NXrWU4Y2W0GQR1XS
SK-LU-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\SelFoUUN3ME2yN{4{PTJ2IN88US=> MVXTRW5ITVJ?
KG-1 NFf3fWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD1{Mz60PVQ3KM7:TR?= NH;KemRUSU6JRWK=
LXF-289 NUT5eJJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;hTWM2OD1{Mz63NVQh|ryP MWTTRW5ITVJ?
HCC1954 NX;KTVJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzpe3ZKSzVyPUK0Mlg5PDRizszN NX3zNW9xW0GQR1XS
Ramos-2G6-4C10 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XiNWlEPTB;Mk[uOFk5OSEQvF2= M2jBOnNCVkeHUh?=
DBTRG-05MG NGnQfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS4TWM2OD1{Nj62OFg5KM7:TR?= NV7tNY5SW0GQR1XS
NCI-H2052 NXfuXnM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO3UYNKSzVyPUK3MlU3QDRizszN Mnv5V2FPT0WU
RMG-I NXHPR4QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu3TI1SUUN3ME2yPU41OTN7IN88US=> MY\TRW5ITVJ?
H9 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNzLkOwNFgh|ryP M4D4V3NCVkeHUh?=
GR-ST NVj2Nm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLZTWM2OD1|Mj60OFU{KM7:TR?= M3r4RXNCVkeHUh?=
Mo-T M1HtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLLTWM2OD1|Mj61NFQ3KM7:TR?= MVLTRW5ITVJ?
SW1088 M{\2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLTTWM2OD1|Mj65PFAyKM7:TR?= NH\QWm5USU6JRWK=
LB2518-MEL Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjtZ2pFUUN3ME2zN{4xPzl5IN88US=> NEDQ[mdUSU6JRWK=
NCI-H82 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\QVWlEPTB;M{OuNVY3OSEQvF2= M4jnXHNCVkeHUh?=
LAMA-84 M4jTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[1foNKSzVyPUO0MlYxPzNizszN NWezO3NOW0GQR1XS
KYSE-450 NFT2[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN2Lk[3O|Yh|ryP NY[4XFNoW0GQR1XS
LU-99A M2jHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXHUIJOUUN3ME2zOU4xODB5IN88US=> NIXCTZhUSU6JRWK=
BE-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN3Lk[1OFUh|ryP Mn34V2FPT0WU
GAK NW\TW4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LNWGlEPTB;M{WuOlk2KM7:TR?= NYrJbVFKW0GQR1XS
NCI-H1573 NYrXc45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LhTGlEPTB;M{WuPFgyQCEQvF2= NYr4PYR7W0GQR1XS
AsPC-1 M3[w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzuTWM2OD1|Nj6xOVI4KM7:TR?= NH3KNHRUSU6JRWK=
HDLM-2 NEiyboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT1TWM2OD1|Nj6zNVYh|ryP NFrr[GxUSU6JRWK=
NCI-H441 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITLcG9KSzVyPUO3MlA3QTFizszN NGjEb4VUSU6JRWK=
CAL-27 NXfacYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN5LkeyN|Eh|ryP NGXRSmtUSU6JRWK=
OVCAR-3 M{jxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN7LkOxPFEh|ryP M1LxfnNCVkeHUh?=
RPMI-8226 NGfn[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrBVmNKSzVyPUO5MlU6QCEQvF2= NXvmOINHW0GQR1XS
EFO-21 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRyLkW4NVQh|ryP NULzUVc{W0GQR1XS
SNU-C2B MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW1SnZKSzVyPUSxMlUxQDRizszN NXu5OmVpW0GQR1XS
VM-CUB-1 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvRWJJNUUN3ME20N{45ODN5IN88US=> MV7TRW5ITVJ?
NCI-H2087 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR3LkCyN|Mh|ryP NX76RZNyW0GQR1XS
EW-16 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XHdWlEPTB;NE[uN|E{PyEQvF2= M3PjcnNCVkeHUh?=
SK-N-AS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDHTWM2OD12Nj63NVY4KM7:TR?= NG\XT5JUSU6JRWK=
COR-L105 NYfoOohJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjrNJVKUUN3ME20Ok45QDV5IN88US=> NFWybmhUSU6JRWK=
DEL NEnXVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR6LkC0Nlkh|ryP NHmzPYlUSU6JRWK=
JVM-2 NGDwTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPndWpKSzVyPUS4MlA2PThizszN M3PaOHNCVkeHUh?=
KARPAS-45 NX7KPXJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTFWGVKSzVyPUS5MlQ2OzhizszN NY\s[mNDW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+55% PEG 300+ddH2O
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID